Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences.
According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer high sensitivity and specificity, as well as a fast and affordable method for targeted NGS oncology testing.
The startup has released beta versions of two targeted sequencing panels, one covering somatic mutations associated with lung and colon cancers, and another for BRCA1 and BRCA2 germline mutations. Additional information about beta users of these panels and their content and methodology were not disclosed.
The investment will help Pillar continue its R&D efforts in tissue-based sequencing panels, as well as support efforts to develop new liquid biopsy products, the firm said.
Source: https://www.genomeweb.com/molecular-diagnostics/cancer-dx-firm-pillar-biosciences-gets-18m-investment-ori-healthcare#.Y8jx8nZByUn
Related Posts
E-Tronic Provides Advanced EV Power Electronics Chips Supporting Efficient Battery Management (February 17, 2025)
Chinese startup E-Tronic specializes in power semiconductors and controller systems for the automotive industry. Their vehicle-grade 12V lithium battery management system (BMS) chip supports front-end analog acquisition, power management, intelligent watchdog, CAN/LIN communication, monitoring and diagnosis, high-side drive, and real-time clock. This enables li
Leto Laboratories Completes Series C Financing of Over 100 Million RMB, Focusing on 0 to 1 Innovative Protein Design and Manufacturing Platform Construction
Leto Laboratories announced the completion of its Series C financing round with a funding size of over 100 million RMB. This round of financing was led by Zhongguancun Science City Corporation and followed by Infiniti Capital and HB Ventures. The round was mainly used for the clinical research of LTC004, a new-generation anti-tumor cytokine class […]
” E-Tronic(Guangzhou) Technology” completes Series A financing led by Infinity Capital
E-Tronic(Guangzhou)Technology Co.,Ltd., a provider of power semiconductors and system solutions for new energy vehicles, has completed its Series A financing with a cumulative amount of over 100 million RMB. This round of financing was led by Infinity Capital, with additional investment from old shareholders Zhongnan Venture Capital and Guangzhou Development
Unveiled the “Shushan” cryogenic CMOS quantum control chipset (March, 2025)
Unveiled the “Shushan” cryogenic CMOS quantum control chipset, including “Gongga” (superconducting qubit control), “Emei” (qubit readout), and “Xiling” (silicon-based qubit control) chips. “Xiling” was presented at ISSCC 2025, reducing system noise and power consumption for large-scale qubit arrays. Ne
Leave a Reply